T cell responses to viral infections - opportunities for peptide vaccination

Frontiers in Immunology

Volumn 5, Issue APR, 2014, Pages

  Huber, Sietske Rosendahl ^a   van Beek, Josine ^a   de Jonge, Jørgen ^a   Luytjes, Willem ^a   van Baarle, Debbie ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Acute; Chronic; DC; Infection; Peptides; Vaccination; Virus

Indexed keywords

ANTIGEN; CYTOKINE; GAG PROTEIN; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE VACCINE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS VACCINE;

APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CROSS PROTECTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOLOGY; NONHUMAN; PAPILLOMAVIRUS INFECTION; REGULATORY T LYMPHOCYTE; REVIEW; SEQUENCE ANALYSIS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VACCINATION; VIRUS INFECTION;

EID: 84900867914     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00171     Document Type: Review

References (117)

1. Knipe DM, Howley PM. Fields Virology. Philadelphia: Lippincott Williams & Wilkins (2013).
2. Lycke E, Hamark B, Johansson M, Krotochwil A, Lycke J, Svennerholm B. Herpes simplex virus infection of the human sensory neuron. An electron microscopy study. Arch Virol (1988) 101:87-104. doi: 10.1007/BF01314654.
3. WHO. Influenza Factsheet. (2009). Available from: http://www.who.int/mediacentre/factsheets/fs211/en/index.html.
4. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva: UNAIDS (2013).
5. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet (1964) 1:702-3. doi:10.1016/S0140-6736(64)91524-7.
6. zur Hausen H, Gissmann L, Steiner W, Dippold W, Dreger I. Human papilloma viruses and cancer. Bibl Haematol (1975) 569-71.
7. + T cells by exogenous cell-associated antigens. Immunity (2002) 17:211-20. doi:10.1016/S1074-7613(02)00365-5.
8. Murphy KT, Walport M. Janeway's Immunobiology. New York: Garland Science (2008).
9. Zajac AJ. Immune response to viruses: cell-mediated immunity. In: Mahy BWJ, van Regenmortel MHV, editors. Encyclopedia of Virology. Birmingham, AL: Elsevier (2008). p. 70-7.
10. Zhang S, Zhang H, Zhao J. The role of CD4 T cell help for CD8 CTL activation. Biochem Biophys Res Commun (2009) 384:405-8. doi:10.1016/j.bbrc.2009.04.134.
11. + lymphocytes. Science (1999) 283:857-60. doi:10.1126/science.283.5403.857.
12. + T cells are required for protection from persistent hepatitis C virus infection. J Exp Med (2003) 197:1645-55. doi:10.1084/jem.20030239.
13. +) T cells during cytomegalovirus infection. Immunol Res (2011) 51:195-204. doi:10.1007/s12026-011-8251-9.
14. Griffin DE, Lin WH, Pan CH. Measles virus, immune control, and persistence. FEMS Microbiol Rev (2012) 36:649-62. doi:10.1111/j.1574-6976.2012.00330.x.
15. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph MS, Mahalingam S, Ruby JC. Cytokines and immunity to viral infections. Immunol Rev (1997) 159:119-35. doi:10.1111/j.1600-065X.1997.tb01011.x.
16. Guo Z, Chen LM, Zeng H, Gomez JA, Plowden J, Fujita T, et al. NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. Am J Respir Cell Mol Biol (2007) 36:263-9. doi:10.1165/rcmb.2006-0283RC.
17. Ling Z, Tran KC, Teng MN. Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J Virol (2009) 83:3734-42. doi:10.1128/JVI.02434-08.
18. + cytotoxic T-cell responses during chronic viral infection. J Virol (1994) 68:8056-63.
19. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med (2013) 19:1305-12. doi:10.1038/nm.3350.
20. + T cells correlate with disease protection against influenza challenge in humans. Nat Med (2012) 18:274-80. doi:10.1038/nm.2612.
21. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu Rev Microbiol (1996) 50:825-54. doi:10.1146/annurev.micro.50.1.825.
22. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 337:1267-74. doi:10.1056/NEJM199710303371803.
23. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 4:123ra125. doi:10.1126/scitranslmed.3003165.
24. Klein MR, Van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med (1995) 181:1365-72. doi:10.1084/jem.181.4.1365.
25. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol (1995) 69:5838-42.
26. Goulder P, Price D, Nowak M, Rowland-Jones S, Phillips R, McMichael A. Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. Immunol Rev (1997) 159:17-29. doi:10.1111/j.1600-065X.1997.tb01004.x.
27. +) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 189:991-8. doi:10.1084/jem.189.6.991.
28. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis (2008) 197:563-71. doi:10.1086/526786.
29. Bronke C, Almeida CA, McKinnon E, Roberts SG, Keane NM, Chopra A, et al. HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. AIDS (2013) 27:899-905. doi:10.1097/QAD.0b013e32835e1616.
30. Plotkin SA, Orenstein WA, Offit PA. Vaccines. Philadelphia: Elsevier (2013).
31. Aichele P, Hengartner H, Zinkernagel RM, Schulz M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med (1990) 171:1815-20. doi:10.1084/jem.171.5.1815.
32. Kast WM, Roux L, Curren J, Blom HJ, Voordouw AC, Meloen RH, et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A (1991) 88:2283-7. doi:10.1073/pnas.88.6.2283.
33. Schulz M, Zinkernagel RM, Hengartner H. Peptide-induced antiviral protection by cytotoxic T cells. Proc Natl Acad Sci U S A (1991) 88:991-3. doi:10.1073/pnas.88.3.991.
34. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A (1996) 93:7855-60. doi:10.1073/pnas.93.15.7855.
35. Toes RE, Van Der Voort EI, Schoenberger SP, Drijfhout JW, Van Bloois L, Storm G, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol (1998) 160:4449-56.
36. Bijker MS, Van Den Eeden SJ, Franken KL, Melief CJ, Van Der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol (2008) 38:1033-42. doi:10.1002/eji.200737995.
37. + CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol (2007) 179:5033-40.
38. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol (2007) 25:171-92. doi:10.1146/annurev.immunol.25.022106.141548.
39. +) T-cell help. Nature (2009) 462:510-3. doi:10.1038/nature08511.
40. + T cell help. J Immunol (1991) 147:4069-73.
41. Toussaint NC, Maman Y, Kohlbacher O, Louzoun Y. Universal peptide vaccines-optimal peptide vaccine design based on viral sequence conservation. Vaccine (2011) 29:8745-53. doi:10.1016/j.vaccine.2011.07.132.
42. Liang TJ. Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 19:869-78. doi:10.1038/nm.3183.
43. + T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol (2007) 178:2746-54.
44. + T cells targeting conserved epitopes: implications for HIV vaccine design. PLoS One (2013) 8:e64405. doi:10.1371/journal.pone.0064405.
45. +) T cells: implications for vaccine development. Hepatology (1999) 30:1088-98. doi:10.1002/hep.510300435.
46. + T-cell responses. Immunol Cell Biol (2013) 91:184-94. doi:10.1038/icb.2012.78.
47. Zhao L, Zhang M, Cong H. Advances in the study of HLA-restricted epitope vaccines. Hum Vaccin Immunother (2013) 9:2566-77.
48. Schellens IM, Kesmir C, Miedema F, Van Baarle D, Borghans JA. An unanticipated lack of consensus cytotoxic T lymphocyte epitopes in HIV-1 databases: the contribution of prediction programs. AIDS (2008) 22:33-7. doi:10.1097/QAD.0b013e3282f15622.
49. + T cell responses to influenza A infection and vaccination in HLA-A2.1 transgenic mice. J Immunol (2011) 187:1895-902. doi:10.4049/jimmunol.1100664.
50. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, Kast WM, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 153:5586-92.
51. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol (2001) 1:209-19. doi:10.1038/35105075.
52. Neefjes J, Ovaa H. A peptide's perspective on antigen presentation to the immune system. Nat Chem Biol (2013) 9:769-75. doi:10.1038/nchembio.1391.
53. +) T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol (2013) 91:96-104. doi:10.1038/icb.2012.54.
54. + T cells. J Biol Chem (2009) 284:9184-91. doi:10.1074/jbc.M809456200.
55. Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol (2013) 43:2554-65. doi:10.1002/eji.201343324.
56. Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol (2010) 40:1973-84. doi:10.1002/eji.201040344.
57. +) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 77:68-76. doi:10.1128/JVI.77.1.68-76.2003.
58. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2007) 13:46-53. doi:10.1038/nm1520.
59. Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, Miranda C, et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PLoS One (2012) 7:e29717. doi:10.1371/journal.pone.0029717.
60. + T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 281:65-78. doi:10.1016/S0022-1759(03)00265-5.
61. Wack A, Openshaw P, O'Garra A. Contribution of cytokines to pathology and protection in virus infection. Curr Opin Virol (2011) 1:184-95. doi:10.1016/j.coviro.2011.05.015.
62. + T cells. Blood (2006) 107:4781-9. doi:10.1182/blood-2005-12-4818.
63. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 8:247-58. doi:10.1038/nri2274.
64. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med (2006) 12:1203-7. doi:10.1038/nm1477.
65. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol (2010) 10:170-81. doi:10.1038/nri2711.
66. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity (2000) 12:171-81. doi:10.1016/S1074-7613(00)80170-3.
67. Napoli J, Bishop GA, McGuinness PH, Painter DM, McCaughan GW. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology (1996) 24:759-65. doi:10.1002/hep.510240402.
68. Odorizzi PM, Wherry EJ. Inhibitory receptors on lymphocytes: insights from infections. J Immunol (2012) 188:2957-65. doi:10.4049/jimmunol.1100038.
69. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol (2009) 10:29-37. doi:10.1038/ni.1679.
70. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 1:751-61. doi:10.1016/S1074-7613(94)80017-0.
71. Li S, Peng L, Zhao W, Zhong H, Zhang F, Yan Z, et al. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses. Vaccine (2011) 29:3695-702. doi:10.1016/j.vaccine.2011.03.002.
72. Wang H, Su X, Zhang P, Liang J, Wei H, Wan M, et al. Recombinant heat shock protein 65 carrying PADRE and HBV epitopes activates dendritic cells and elicits HBV-specific CTL responses. Vaccine (2011) 29:2328-35. doi:10.1016/j.vaccine.2010.12.124.
73. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol (1989) 19:2237-42. doi:10.1002/eji.1830191209.
74. La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J Infect Dis (2012) 205:1294-304. doi:10.1093/infdis/jis107.
75. + T cell to a fully functional tumor killer cell. Cancer Res (2002) 62:6438-41.
76. Schoenberger SP, Toes RE, Van Der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 393:480-3. doi:10.1038/31002.
77. Trinchieri G. Interleukin-12 and its role in the generation of TH1 cells. Immunol Today (1993) 14:335-8. doi:10.1016/0167-5699(93)90230-I.
78. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med (1996) 184:747-52. doi:10.1084/jem.184.2.747.
79. Melchers M, Matthews K, De Vries RP, Eggink D, Van Montfort T, Bontjer I, et al. A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology (2011) 8:48. doi:10.1186/1742-4690-8-48.
80. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 101:15440-5. doi:10.1073/pnas.0406740101.
81. Chua BY, Johnson D, Tan A, Earnest-Silveira L, Sekiya T, Chin R, et al. Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One (2012) 7:e47492. doi:10.1371/journal.pone.0047492.
82. + T cells. J Immunol (2007) 179:2187-94.
83. Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, et al. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol Immunother (2013) 62:1149-59. doi:10.1007/s00262-013-1435-5.
84. den Boer AT, Diehl L, Van Mierlo GJ, Van Der Voort EI, Fransen MF, Krimpenfort P, et al. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol (2001) 167:2522-8.
85. Harris RC, Chianese-Bullock KA, Petroni GR, Schaefer JT, Brill LB II, Molhoek KR, et al. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. J Immunother (2012) 35:78-88. doi:10.1097/CJI.0b013e31823731a4.
86. Welters MJ, Bijker MS, Van Den Eeden SJ, Franken KL, Melief CJ, Offringa R, et al. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. Vaccine (2007) 25:1379-89. doi:10.1016/j.vaccine.2006.10.049.
87. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-Van Der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 361:1838-47. doi:10.1056/NEJMoa0810097.
88. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One (2008) 3:e2636. doi:10.1371/journal.pone.0002636.
89. Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, et al. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One (2010) 5:e11995. doi:10.1371/journal.pone.0011995.
90. +) CTL responses with particulate vaccine delivery systems. Eur J Pharm Sci (2012) 45:482-91. doi:10.1016/j.ejps.2011.08.016.
91. Gregoriadis G, Ryman BE. Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases. Biochem J (1971) 124:58.
92. Matsui M, Kohyama S, Suda T, Yokoyama S, Mori M, Kobayashi A, et al. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice. Biochem Biophys Res Commun (2010) 391:1494-9. doi:10.1016/j.bbrc.2009.12.100.
93. + T-cell responses by targeting DC-SIGN on dendritic cells. J Control Release (2012) 160:88-95. doi:10.1016/j.jconrel.2012.02.007.
94. Bungener L, Idema J, Ter Veer W, Huckriede A, Daemen T, Wilschut J. Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens. J Liposome Res (2002) 12:155-63. doi:10.1081/LPR-120004789.
95. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM, et al. The virosome concept for influenza vaccines. Vaccine (2005) 23(Suppl 1):S26-38. doi:10.1016/j.vaccine.2005.04.026.
96. Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, De Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One (2012) 7:e36812. doi:10.1371/journal.pone.0036812.
97. Klade CS, Schuller E, Boehm T, Von Gabain A, Manns MP. Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine (2012) 30:2943-50. doi:10.1016/j.vaccine.2012.02.070.
98. El-Awady MK, El Gendy M, Waked I, Tabll AA, El Abd Y, Bader El Din N, et al. Immunogenicity and safety of HCV E1E2 peptide vaccine in chronically HCV-infected patients who did not respond to interferon based therapy. Vaccine (2013). doi:10.1016/j.vaccine.2013.07.074.
99. Ninomiya A, Ogasawara K, Kajino K, Takada A, Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine (2002) 20:3123-9. doi:10.1016/S0264-410X(02)00261-X.
100. Gao X, Wang W, Li Y, Zhang S, Duan Y, Xing L, et al. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge. Antiviral Res (2013) 98:4-11. doi:10.1016/j.antiviral.2013.01.010.
101. NIAID. The Jordan Report: Accelerated Development of Vaccines. Appendix A: Status of Vaccine Research and Development. National Institute of Allergy and Infectious Diseases (2012). p. 153-78.
102. Pleguezuelos O, Robinson S, Stoloff GA, Caparros-Wanderley W. Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine (2012) 30:4655-60. doi:10.1016/j.vaccine.2012.04.089.
103. Rose MA, Zielen S, Baumann U. Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines (2012) 11:595-607. doi:10.1586/erv.12.31.
104. + T cells predict severe pandemic influenza A virus infection. Am J Respir Crit Care Med (2012) 186:1292-7. doi:10.1164/rccm.201207-1245OC.
105. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 181:1047-58. doi:10.1084/jem.181.3.1047.
106. Feuth T, Arends JE, Lieveld FI, Mundt MW, Hoepelman AI, Siersema PD, et al. Impact of transient elastography on clinical decision-making in patients with chronic viral hepatitis. Scand J Gastroenterol (2013) 48:1074-81. doi:10.3109/00365521.2013.819441.
107. +) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 191:1269-80. doi:10.1084/jem.191.8.1269.
108. +) T cell immunity in children. J Virol (2011) 85:11995-2000. doi:10.1128/JVI.05213-11.
109. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis (2011) 204:845-53. doi:10.1093/infdis/jir436.
110. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol (2006) 176:6333-9.
111. +)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol (2002) 168:5893-9.
112. + T cells. Blood (2003) 101:2711-20. doi:10.1182/blood-2002-07-2103.
113. Chen WH, Kozlovsky BF, Effros RB, Grubeck-Loebenstein B, Edelman R, Sztein MB. Vaccination in the elderly: an immunological perspective. Trends Immunol (2009) 30:351-9. doi:10.1016/j.it.2009.05.002.
114. Blomberg BB, Frasca D. Quantity, not quality, of antibody response decreased in the elderly. J Clin Invest (2011) 121:2981-3. doi:10.1172/JCI58406.
115. El-Awady MK, Tabll AA, Yousif H, El-Abd Y, Reda M, Khalil SB, et al. Murine neutralizing antibody response and toxicity to synthetic peptides derived from E1 and E2 proteins of hepatitis C virus. Vaccine (2010) 28:8338-44. doi:10.1016/j.vaccine.2009.11.059.
116. Testa JS, Shetty V, Hafner J, Nickens Z, Kamal S, Sinnathamby G, et al. MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. PLoS One (2012) 7:e48484. doi:10.1371/journal.pone.0048484.
117. Zhou C, Zhou L, Chen YH. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Vaccine (2012) 30:3463-9. doi:10.1016/j.vaccine.2012.03.021.